已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

A First-in-Human, Phase 1, Multicenter, Open-label, Dose-Escalation Study of PCA062, an Antibody-Drug Conjugate Targeting P-Cadherin, in Patients with Solid Tumors.

结合 医学 药代动力学 药理学 化学 癌症 抗体-药物偶联物 癌症研究 临床研究阶段 药效学 内科学
作者
Matteo Duca,Darren W.T. Lim,Pete Anderson,Shunji Takahashi,John Sarantopoulos,Andrea Varga,Joseph Anthony D'Alessio,Tinya Abrams,Qing Sheng,Eugene Youchin Tan,Maria Santos Rosa,Juan Gonzalez-Maffe,Janna Sand-Dejmek,Claire Fabre,Miguel Martin
出处
期刊:Molecular Cancer Therapeutics [American Association for Cancer Research]
标识
DOI:10.1158/1535-7163.mct-21-0652
摘要

This first-in-human (FIH), phase 1, multicenter, open-label study was conducted to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy, and to establish the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) of PCA062 in patients with solid tumors. Adult patients with any solid tumor type and having a documented P-cadherin-positive tumor were enrolled; exceptions to P-cadherin positivity requirement were head and neck squamous cell carcinomas (HNSCC) and esophageal squamous cell carcinoma (ESCC). Dose escalation was guided by an adaptive Bayesian logistic regression model with escalation with overdose control to determine the MTD/RDE. Forty-seven patients were treated at 10 different dose levels of PCA062, ranging from 0.4 to 5.0 mg/kg Q2W administered as a 1-hour intravenous infusion. All enrolled patients discontinued the treatment; primary reason for discontinuation was progressive disease (78.7%). All 47 patients experienced at least one AE, of which 32 patients had a grade {greater than or equal to}3 AE and 37 patients experienced AEs suspected to be study drug related. The MTD of PCA062 was 3.6 mg/kg Q2W and thrombocytopenia was reported as a DLT that was attributed to the known toxicities of the DM1 payload with no P cadherin-related toxicities. PK was proportional, and no patients developed antidrug antibodies, suggesting adequate exposure at the doses tested. One patient out of 47 achieved a partial response and there was no correlation between tumor P-cadherin expression and clinical efficacy. Due to limited anti-tumor activity at the maximally tolerated dose level, Novartis has terminated clinical development of PCA062 (NCT02375958).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xixi完成签到 ,获得积分10
刚刚
正直冰淇淋完成签到,获得积分10
2秒前
AryaZzz完成签到 ,获得积分10
3秒前
思源的应助被小豆糕采纳,获得10
3秒前
3秒前
Akim的应助被小豆糕采纳,获得10
3秒前
6秒前
小李发大财完成签到 ,获得积分10
6秒前
干净涵梅完成签到,获得积分10
6秒前
7秒前
Owen的应助被bianco2007采纳,获得10
9秒前
liza发布了新的文献求助10
10秒前
子皿完成签到,获得积分10
11秒前
11秒前
moriaty发布了新的文献求助20
11秒前
DW的应助被Only2546采纳,获得10
11秒前
wangliying完成签到 ,获得积分10
13秒前
开朗向彤发布了新的文献求助10
14秒前
小只发布了新的文献求助10
14秒前
含蓄的蜻蜓完成签到,获得积分10
14秒前
17秒前
可靠元枫完成签到 ,获得积分10
18秒前
bianco2007完成签到,获得积分10
20秒前
何佳慧完成签到 ,获得积分10
20秒前
无花果的应助被热爱学习采纳,获得30
21秒前
哎古完成签到 ,获得积分10
21秒前
Owen的应助被飘逸小之采纳,获得10
22秒前
yyq完成签到,获得积分10
22秒前
乐乐的应助被多多采纳,获得10
22秒前
卿亦佳人发布了新的文献求助10
24秒前
爱吃肉肉的手性分子完成签到,获得积分10
26秒前
Jasper的应助被布洛芬采纳,获得10
27秒前
乐观寻芹完成签到,获得积分10
28秒前
LeoYiS214完成签到,获得积分10
32秒前
32秒前
33秒前
yujihaiasdfg完成签到,获得积分10
34秒前
11完成签到 ,获得积分10
34秒前
崔京成完成签到 ,获得积分10
34秒前
37秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184889
求助须知:如何正确求助?哪些是违规求助? 9573836
关于积分的说明 21833242
捐赠科研通 7782263
什么是DOI,文献DOI怎么找? 3434429
关于科研通互助平台的介绍 2558581
邀请新用户注册赠送积分活动 2481082